BioSpace News Archive

Peerbridge Health is collaborating with Northwell Health on their newly launched AFib Center of Excellence, a mutli-displinary effort that optimizes treatment for patients with atrial fibrillation (AFib).

Transfusions of blood plasma donated by people who have already recovered from infection with the pandemic virus may help other patients hospitalized with COVID-19, a new international study shows.

The global RFID in Healthcare Market is expected to reach USD 12.89 Billion by 2027, according to a new report by Emergen Research.

The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced that the organization has raised more than $8 million since the beginning of the pandemic of which 100% will be used directly for research and education programs focused on achieving its mission of making Lyme disease easy to diagnose and simple to cure.

Irvine-based Biogennix announced today that 2021 was the best sales year in company history.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eleven employees nonqualified stock options to purchase an aggregate of 63,400 shares of its common stock with an exercise price of $6.30, which is equal to the closing price of Gritstone’s common stock on January 13, 2022, the grant date of the awards.

Roivant Sciences announced that its CEO Matt Gline will present at two upcoming conferences.

Advanced analytical tools such as SWOT analysis and Porter’s Five Forces analysis along with details diagrams, graphs, and figures have been applied in this study.

Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT, the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development.